Orthofix Medical Inc.
OFIXOrthofix Medical Inc. in brief
Orthofix Medical Inc. is a listed company in the Medical Devices industry, based in Lewisville, Texas, USA. Its market value was $377 M on 15 October 2026, which makes it the 13,802nd largest listed company in the world and the 2,709th largest in the USA on this site. In the year to December 2025 it had sales of $822 M and a net loss of $92 M. Massimo Calafiore is its chief executive. Its largest business segments by sales in 2025 were Global Spine (84%) and Global Limb Reconstruction (16%). By market, the largest shares of its 2025 sales came from USA (83%), Italy (3%) and UK (2%). Its shares trade under the symbol OFIX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Orthofix Medical Inc.
Orthofix Medical is a diversified, global medical device company focused on improving patients lives by providing superior reconstruction and regenerative orthopedic and spine solutions to physicians worldwide. The company products are distributed in more than 70 countries around the world via Orthofix sales representatives, stocking distributors and subsidiaries. It has more than 1000 employees around the world are dedicated to the development, manufacturing and distribution of orthopedic and spine products and regenerative tissue forms. The headquarters is in USA.
Orthofix Medical Inc. timeline
- 1992
- 🔔· approximateInitial public offering on Nasdaq
- 1998
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- ✎Renamed Orthofix Medical Inc.Formerly Orthofix International N V.
- 2025
- 💰Record revenue of $822 millionFY2025, the highest of the 8 years on record.
Events of Orthofix Medical Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,042 (Jan 2020) · #2,355 (Jan 2021) · #3,035 (Jan 2022) · #2,889 (Dec 2022) · #2,390 (Jul 2023) · #2,576 (Jan 2024) · #1,225 (Mar 2026) · #2,632 (Aug 2026) · #2,696 (Sep 2026) · #2,713 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.5×
- Price / book
- 0.8×
- Free cash flow yield
- -0.3%
- Net margin (TTM)
- -5.4%
- Operating margin
- -9.9%
- Return on equity
- -10.0%
- Liabilities / assets
- 47.1%
- Net debt
- $75M
- Revenue growth
- +2.9%
- R&D / revenue
- 8.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $822M | +2.9% | $-81M | $-92M | -11.2% |
| Dec 2024 | $799M | +7.1% | $-85M | $-126M | -15.8% |
| Dec 2023 | $747M | +62.1% | $-139M | $-151M | -20.3% |
| Dec 2022 | $461M | -0.8% | $-13M | $-20M | -4.3% |
| Dec 2021 | $464M | +14.2% | $-8M | $-38M | -8.3% |
| Dec 2020 | $407M | -11.6% | $-6M | $3M | 0.6% |
| Dec 2019 | $460M | +1.5% | $-19M | $-28M | -6.2% |
| Dec 2018 | $453M | — | $30M | $14M | 3.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $33M | $35M | $-1M | $-2.33 | — |
| Dec 2024 | $26M | $35M | $-9M | $-3.30 | — |
| Dec 2023 | $-46M | $60M | $-106M | $-4.12 | — |
| Dec 2022 | $-12M | $21M | $-33M | $-0.98 | — |
| Dec 2021 | $18M | $18M | $1M | $-1.95 | — |
| Dec 2020 | $74M | $15M | $59M | $0.13 | — |
| Dec 2019 | $32M | $19M | $13M | $-1.51 | — |
| Dec 2018 | $50M | $14M | $36M | $0.72 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $208M (+1.1% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 2, 20268-KCurrent reportRegulation FD disclosure
- Jun 11, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 21, 20268-KCurrent reportRegulation FD disclosure
- May 5, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 29, 2026DEF 14AProxy statement
- Apr 9, 20268-KCurrent reportResults of operations · Directors or officers changed
- Feb 24, 202610-KAnnual report · period to Dec 2025
Official filings of Orthofix Medical Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $822 M
- Operating income
- $-81 M
- Net income
- $-92 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $851 M
- Total liabilities
- $401 M
- Total equity
- $450 M
As of December-2025
Top 100 institutional investors in Orthofix Medical Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Juniper Investment Company, LLC | 4,792,043 | +349,500 (+7.87%) | 11.76% | $45 M | Nov 16, 2026 |
| 2 | Engine Capital Management, LP | 4,575,675 | 0 (0.00%) | 11.23% | $43 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 3,863,335 | +536,775 (+16.14%) | 9.48% | $36 M | Nov 13, 2026 |
| 4 | Rubric Capital Management LP | 3,721,715 | 0 (0.00%) | 9.13% | $35 M | Nov 16, 2026 |
| 5 | Armistice Capital, LLC | 3,624,000 | +360,000 (+11.03%) | 8.89% | $34 M | Nov 16, 2026 |
| 6 | Paradigm Capital Management Inc/ny | 3,293,899 | -6,600 (-0.20%) | 8.08% | $31 M | Nov 13, 2026 |
| 7 | Vanguard Capital Management LLC | 1,702,701 | -28,407 (-1.64%) | 4.18% | $16 M | Nov 13, 2026 |
| 8 | State Street Corp | 1,001,547 | +48,399 (+5.08%) | 2.46% | $9 M | Nov 12, 2026 |
| 9 | Millennium Management LLC | 949,339 | +87,309 (+10.13%) | 2.33% | $9 M | Nov 16, 2026 |
| 10 | Geode Capital Management, LLC | 925,350 | -122,731 (-11.71%) | 2.27% | $9 M | Nov 6, 2026 |
| 11 | Acadian Asset Management LLC | 842,531 | -44,669 (-5.03%) | 2.07% | $8 M | Nov 9, 2026 |
| 12 | Dimensional Fund Advisors LP | 671,870 | -59,768 (-8.17%) | 1.65% | $6 M | Nov 4, 2026 |
| 13 | AQR Capital Management LLC | 651,212 | -236,070 (-26.61%) | 1.60% | $6 M | Nov 16, 2026 |
| 14 | Goldman Sachs Group Inc | 600,123 | +153,983 (+34.51%) | 1.47% | $6 M | Nov 16, 2026 |
| 15 | Morgan Stanley | 597,966 | +302,310 (+102.25%) | 1.47% | $6 M | Nov 13, 2026 |
| 16 | Jacobs Levy Equity Management, Inc | 430,713 | -50,123 (-10.42%) | 1.06% | $4 M | Nov 16, 2026 |
| 17 | Bank Of America Corp /de/ | 404,395 | +112,568 (+38.57%) | 0.99% | $4 M | Nov 16, 2026 |
| 18 | Vanguard Portfolio Management LLC | 399,058 | -5,781 (-1.43%) | 0.98% | $4 M | Nov 13, 2026 |
| 19 | Northern Trust Corp | 357,994 | -5,890 (-1.62%) | 0.88% | $3 M | Nov 16, 2026 |
| 20 | AYAL Capital Advisors Ltd | 341,588 | -433,833 (-55.95%) | 0.84% | $3 M | Nov 16, 2026 |
| 21 | FMR LLC | 320,690 | +55,213 (+20.80%) | 0.79% | $3 M | Nov 10, 2026 |
| 22 | Charles Schwab Investment Management Inc | 306,119 | -28,498 (-8.52%) | 0.75% | $3 M | Nov 16, 2026 |
| 23 | Russell Investments Group, Ltd. | 274,157 | +74,838 (+37.55%) | 0.67% | $3 M | Nov 6, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 270,194 | +2,885 (+1.08%) | 0.66% | $3 M | Nov 13, 2026 |
| 25 | Tudor Investment Corp Et Al | 267,881 | -1,157 (-0.43%) | 0.66% | $3 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Bridgeway Capital Management, LLC | 240,953 | +128,348 (+113.98%) | 0.59% | $2 M | Nov 16, 2026 |
| 27 | UBS Group AG | 212,748 | +24,747 (+13.16%) | 0.52% | $2 M | Nov 10, 2026 |
| 28 | Arrowstreet Capital, Limited Partnership | 199,762 | -144,443 (-41.96%) | 0.49% | $2 M | Nov 13, 2026 |
| 29 | GAMCO Investors, Inc. Et Al | 198,800 | 0 (0.00%) | 0.49% | $2 M | Nov 12, 2026 |
| 30 | Voya Investment Management LLC | 197,930 | +81,298 (+69.70%) | 0.49% | $2 M | Nov 10, 2026 |
| 31 | Creative Planning | 191,417 | +177,506 (+1276.01%) | 0.47% | $2 M | Nov 2, 2026 |
| 32 | Lazard Asset Management LLC | 171,820 | -2,082 (-1.20%) | 0.42% | $2 M | Nov 16, 2026 |
| 33 | Jpmorgan Chase & Co | 163,572 | -1,294 (-0.78%) | 0.40% | $2 M | Nov 12, 2026 |
| 34 | Empowered Funds, LLC | 138,453 | +103,348 (+294.40%) | 0.34% | $1 M | Nov 13, 2026 |
| 35 | Point72 Asset Management, L.P. | 133,761 | +60,740 (+83.18%) | 0.33% | $1 M | Nov 16, 2026 |
| 36 | Y-Intercept (Hong Kong) Ltd | 131,898 | +71,367 (+117.90%) | 0.32% | $1 M | Oct 16, 2026 |
| 37 | Bank of New York Mellon Corp | 121,232 | +2,103 (+1.77%) | 0.30% | $1 M | Nov 5, 2026 |
| 38 | Victory Capital Management Inc | 119,772 | +17,736 (+17.38%) | 0.29% | $1 M | Nov 10, 2026 |
| 39 | Gabelli Funds LLC | 109,300 | 0 (0.00%) | 0.27% | $1 M | Nov 12, 2026 |
| 40 | Nuveen, LLC | 107,368 | -79,425 (-42.52%) | 0.26% | $1 M | Nov 10, 2026 |
| 41 | Price T Rowe Associates Inc /MD/ | 104,998 | 0 (0.00%) | 0.26% | $1 M | Nov 16, 2026 |
| 42 | Deutsche Bank AG\ | 87,362 | -4,946 (-5.36%) | 0.21% | $1 M | Nov 6, 2026 |
| 43 | Ameriprise Financial Inc | 83,941 | +3,123 (+3.86%) | 0.21% | $1 M | Nov 16, 2026 |
| 44 | Renaissance Technologies LLC | 79,891 | -16,900 (-17.46%) | 0.20% | $1 M | Nov 12, 2026 |
| 45 | American Century Companies Inc | 78,693 | +5,760 (+7.90%) | 0.19% | $1 M | Nov 12, 2026 |
| 46 | Invesco Ltd. | 72,513 | -597 (-0.82%) | 0.18% | $1 M | Nov 12, 2026 |
| 47 | Great Lakes Advisors, LLC | 70,035 | -65,206 (-48.21%) | 0.17% | $1 M | Nov 6, 2026 |
| 48 | Algert Global LLC | 66,110 | New | 0.16% | $1 M | Nov 17, 2026 |
| 49 | XTX Topco Ltd | 63,892 | +40,814 (+176.85%) | 0.16% | $1 M | Nov 16, 2026 |
| 50 | Quantinno Capital Management LP | 60,053 | -23,235 (-27.90%) | 0.15% | $1 M | Nov 13, 2026 |
| 51 | Global Strategic Investment Solutions, LLC | 57,875 | 0 (0.00%) | 0.14% | $1 M | Oct 16, 2026 |
| 52 | Rhumbline Advisers | 50,968 | -5,243 (-9.33%) | 0.13% | $0 M | Nov 10, 2026 |
| 53 | Tejara Capital Ltd | 47,820 | -10,900 (-18.56%) | 0.12% | $0 M | Nov 9, 2026 |
| 54 | BNP Paribas Financial Markets | 41,731 | -55,866 (-57.24%) | 0.10% | $0 M | Nov 12, 2026 |
| 55 | Barclays PLC | 39,642 | +8,882 (+28.88%) | 0.10% | $0 M | Nov 6, 2026 |
| 56 | Alliancebernstein L.P. | 38,749 | -4,400 (-10.20%) | 0.10% | $0 M | Nov 16, 2026 |
| 57 | Boston Partners | 36,989 | +10,535 (+39.82%) | 0.09% | $0 M | Nov 10, 2026 |
| 58 | Susquehanna Portfolio Strategies, LLC | 36,634 | -38,383 (-51.17%) | 0.09% | $0 M | Nov 16, 2026 |
| 59 | State of Wyoming | 34,750 | +15,651 (+81.95%) | 0.09% | $0 M | Oct 28, 2026 |
| 60 | Vanguard Global Advisers, LLC | 34,439 | +174 (+0.51%) | 0.08% | $0 M | Nov 13, 2026 |
| 61 | CenterBook Partners LP | 33,988 | New | 0.08% | $0 M | Nov 2, 2026 |
| 62 | Gsa Capital Partners LLP | 32,221 | +4,420 (+15.90%) | 0.08% | $0 M | Nov 16, 2026 |
| 63 | Centiva Capital, LP | 31,139 | New | 0.08% | $0 M | Nov 13, 2026 |
| 64 | RBF Capital, LLC | 30,000 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 65 | Mercer Global Advisors Inc /adv | 28,248 | -1,521 (-5.11%) | 0.07% | $0 M | Nov 16, 2026 |
| 66 | Fox Run Management, L.L.C. | 26,919 | New | 0.07% | $0 M | Nov 12, 2026 |
| 67 | D. E. Shaw & Co., Inc. | 25,735 | +14,335 (+125.75%) | 0.06% | $0 M | Nov 16, 2026 |
| 68 | Ieq Capital, LLC | 25,479 | -11,789 (-31.63%) | 0.06% | $0 M | Nov 10, 2026 |
| 69 | Mariner, LLC | 24,583 | -10,794 (-30.51%) | 0.06% | $0 M | Nov 12, 2026 |
| 70 | Strs Ohio | 23,600 | +600 (+2.61%) | 0.06% | $0 M | Oct 30, 2026 |
| 71 | Squarepoint Ops LLC | 22,753 | New | 0.06% | $0 M | Nov 9, 2026 |
| 72 | Citigroup Inc | 22,630 | -15,638 (-40.86%) | 0.06% | $0 M | Nov 4, 2026 |
| 73 | Assenagon Asset Management S.A. | 21,310 | -21,310 (-50.00%) | 0.05% | $0 M | Oct 15, 2026 |
| 74 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 19,625 | +1,005 (+5.40%) | 0.05% | $0 M | Nov 16, 2026 |
| 75 | Fifth Third Wealth Advisors LLC | 18,986 | New | 0.05% | $0 M | Oct 22, 2026 |
| 76 | MetLife Investment Management, LLC | 18,528 | -5,399 (-22.56%) | 0.05% | $0 M | Nov 16, 2026 |
| 77 | Wealth Enhancement Advisory Services, LLC | 13,956 | -3,944 (-22.03%) | 0.03% | $0 M | Oct 13, 2026 |
| 78 | Engineers Gate Manager LP | 12,718 | New | 0.03% | $0 M | Nov 16, 2026 |
| 79 | Quadrature Capital Ltd | 12,626 | New | 0.03% | $0 M | Nov 13, 2026 |
| 80 | Teton Advisors, LLC | 12,500 | -4,000 (-24.24%) | 0.03% | $0 M | Nov 12, 2026 |
| 81 | Manufacturers Life Insurance Company, The | 12,003 | -507 (-4.05%) | 0.03% | $0 M | Nov 13, 2026 |
| 82 | Axq Capital, LP | 11,962 | New | 0.03% | $0 M | Nov 12, 2026 |
| 83 | Police & Firemen's Retirement System of New Jersey | 10,658 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 84 | Vise Technologies, Inc. | 10,229 | New | 0.03% | $0 M | Oct 29, 2026 |
| 85 | State Board Of Administration Of Florida Retirement System | 10,072 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 86 | New York State Common Retirement Fund | 8,180 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 87 | Aquatic Capital Management LLC | 8,144 | New | 0.02% | $0 M | Nov 16, 2026 |
| 88 | Wells Fargo & Company/mn | 8,078 | -26,003 (-76.30%) | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Tower Research Capital LLC (TRC) | 7,688 | +4,385 (+132.76%) | 0.02% | $0 M | Nov 16, 2026 |
| 90 | Arax Advisory Partners | 4,408 | -309 (-6.55%) | 0.01% | $0 M | Nov 12, 2026 |
| 91 | HighMark Wealth Management LLC | 4,310 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 92 | Legal & General Group Plc | 4,070 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 93 | Ameritas Investment Partners, Inc. | 3,494 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 94 | Parallel Advisors, LLC | 3,269 | +3,140 (+2434.11%) | 0.01% | $0 M | Nov 3, 2026 |
| 95 | Osaic Holdings, Inc. | 2,601 | +95 (+3.79%) | 0.01% | $0 M | Nov 12, 2026 |
| 96 | Nisa Investment Advisors, LLC | 2,561 | -45 (-1.73%) | 0.01% | $0 M | Oct 20, 2026 |
| 97 | Royal Bank Of Canada | 2,332 | +640 (+37.83%) | 0.01% | $0 M | Nov 16, 2026 |
| 98 | Public Employees Retirement System Of Ohio | 1,803 | -36,290 (-95.27%) | 0.00% | $0 M | Nov 16, 2026 |
| 99 | Rockefeller Capital Management L.P. | 1,656 | New | 0.00% | $0 M | Nov 13, 2026 |
| 100 | Signaturefd, LLC | 1,482 | +984 (+197.59%) | 0.00% | $0 M | Oct 23, 2026 |
Mutual funds holding Orthofix Medical Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.21 M | $11 M | 3.0% | <0.01% | +3.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.03 M | $9 M | 2.5% | 0.01% | +7.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 440,869 | $5 M | 1.1% | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 473,856 | $4 M | 1.2% | <0.01% | +7.7% | Jun 30, 2026 |
| 🇺🇸 Paradigm Micro-Cap FundPARADIGM FUNDS ADVISOR LLC | 400,000 | $4 M | 0.98% | 2.0% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 349,079 | $3 M | 0.86% | 0.02% | +4.6% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 180,783 | $2 M | 0.44% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 201,328 | $2 M | 0.49% | 0.01% | +4.6% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 149,976 | $2 M | 0.37% | 0.13% | +43% | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 189,113 | $2 M | 0.46% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 187,109 | $2 M | 0.46% | <0.01% | +1.0% | May 31, 2026 |
| 🇺🇸 iShares U.S. Medical Devices ETFBlackRock Fund Advisors | 189,289 | $2 M | 0.46% | 0.06% | +11% | Jun 30, 2026 |
| 🇺🇸 1290 VT GAMCO Small Company Value PortfolioEquitable Investment Management Group, LLC | 185,000 | $2 M | 0.45% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 120,099 | $1 M | 0.29% | 0.02% | −8.1% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 152,638 | $1 M | 0.37% | 0.21% | +97% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 135,419 | $1 M | 0.33% | 0.08% | +37% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 98,582 | $1 M | 0.24% | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 90,212 | $1 M | 0.22% | <0.01% | −32% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 90,143 | $1 M | 0.22% | 0.11% | +37% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 89,604 | $1 M | 0.22% | <0.01% | −20% | Jul 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 106,491 | $1 M | 0.26% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Paradigm Select FundPARADIGM FUNDS ADVISOR LLC | 100,000 | $1 M | 0.25% | 0.32% | no change | Jun 30, 2026 |
| 🇺🇸 The Gabelli Small Cap Growth FundGabelli Funds, LLC | 96,800 | $1 M | 0.24% | 0.05% | −31% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 96,082 | $1 M | 0.24% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 96,026 | $1 M | 0.24% | 0.07% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 94,025 | $1 M | 0.23% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 75,591 | $1 M | 0.19% | 0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 75,000 | $1 M | 0.18% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 72,576 | $1 M | 0.18% | 0.05% | +589% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P Health Care Equipment ETFSSGA Funds Management, Inc. | 73,594 | $1 M | 0.18% | 0.44% | +47% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 70,822 | $1 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 52,608 | $1 M | 0.13% | 0.02% | +7.8% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 65,308 | $1 M | 0.16% | 0.02% | −17% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 50,572 | $1 M | 0.12% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 60,186 | $1 M | 0.15% | <0.01% | +6.0% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 55,939 | $1 M | 0.14% | 0.02% | +17% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 53,295 | $0 M | 0.13% | 0.05% | −8.2% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 52,948 | $0 M | 0.13% | <0.01% | +2.6% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 39,483 | $0 M | 0.10% | 0.02% | −10.0% | Jul 31, 2026 |
| 🇺🇸 Inspire Small/Mid Cap ETFCWM Advisors, LLC | 47,055 | $0 M | 0.12% | 0.14% | +48% | May 31, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 46,768 | $0 M | 0.11% | 0.09% | +15% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 43,107 | $0 M | 0.11% | 0.18% | +13% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 40,719 | $0 M | 0.10% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya Small Company PortfolioVoya Investments, LLC | 39,961 | $0 M | 0.10% | 0.17% | +8.6% | Jun 30, 2026 |
| 🇺🇸 Voya MI Dynamic Small Cap FundVoya Investments, LLC | 35,895 | $0 M | 0.09% | 0.18% | +13% | May 31, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 35,105 | $0 M | 0.09% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 33,996 | $0 M | 0.08% | 0.03% | −25% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 24,835 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 31,138 | $0 M | 0.08% | 0.02% | +9.9% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 22,050 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 27,534 | $0 M | 0.07% | 0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 21,334 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 27,318 | $0 M | 0.07% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 21,135 | $0 M | 0.05% | <0.01% | +227% | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Value Factor ETFThe Vanguard Group, Inc. | 25,943 | $0 M | 0.06% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 25,928 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 24,938 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 19,325 | $0 M | 0.05% | 0.02% | +14% | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 23,621 | $0 M | 0.06% | 0.07% | −14% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 21,491 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 21,185 | $0 M | 0.05% | <0.01% | +45% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 20,970 | $0 M | 0.05% | 0.01% | +9.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Multifactor ETFThe Vanguard Group, Inc. | 20,077 | $0 M | 0.05% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 19,560 | $0 M | 0.05% | 0.07% | −11% | May 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 15,120 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 15,072 | $0 M | 0.04% | <0.01% | +6.5% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR US Small Cap Low Volatility Index ETFSSGA Funds Management, Inc. | 19,160 | $0 M | 0.05% | 0.07% | +0.0% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 17,980 | $0 M | 0.04% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 17,050 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 16,633 | $0 M | 0.04% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 16,603 | $0 M | 0.04% | 0.06% | −1.6% | Jun 30, 2026 |
| 🇺🇸 TETON Westwood Mighty Mites FundTeton Advisors, LLC | 16,500 | $0 M | 0.04% | 0.07% | −4.6% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 16,237 | $0 M | 0.04% | <0.01% | +116% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 15,772 | $0 M | 0.04% | <0.01% | +77% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 15,085 | $0 M | 0.04% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 14,565 | $0 M | 0.04% | <0.01% | +2.1% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 10,726 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 13,566 | $0 M | 0.03% | 0.01% | +6.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Multifactor FundThe Vanguard Group, Inc. | 12,537 | $0 M | 0.03% | 0.04% | no change | May 31, 2026 |
| 🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC | 12,500 | $0 M | 0.03% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 10,313 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 7,374 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 9,509 | $0 M | 0.02% | 0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,352 | $0 M | 0.02% | 0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 9,122 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,042 | $0 M | 0.02% | 0.04% | +30% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 8,826 | $0 M | 0.02% | 0.02% | −4.5% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 8,713 | $0 M | 0.02% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 6,664 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 6,348 | $0 M | 0.02% | 0.02% | +6.5% | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Quality Factor ETFThe Vanguard Group, Inc. | 7,557 | $0 M | 0.02% | 0.02% | −58% | May 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 7,069 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 6,953 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 6,867 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 6,549 | $0 M | 0.02% | 0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 5,000 | $0 M | 0.01% | <0.01% | +56% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,376 | $0 M | 0.02% | 0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,098 | $0 M | 0.01% | 0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,633 | $0 M | 0.01% | <0.01% | +2.9% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,847 | $0 M | 0.01% | 0.01% | +31% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Orthofix Medical Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Juniper Investment Company, LLC10% owner | Buyindirect | +14,803 | $7.040 | $104 K | 4.46 M | Form 4 |
| filed | Juniper Investment Company, LLC10% owner | Buyindirect | +675,000 | $7.411 | $5.0 M | 4.45 M | Form 4 |
| filed | Patrick FisherPresident, Global Limb Recon | Sell10b5-1 plan | -150 | $9.070 | $1 K | 50,769 | Form 4 |
| filed | Patrick FisherPresident, Global Limb Recon | Sell10b5-1 plan | -150 | $9.440 | $1 K | 50,919 | Form 4 |
| filed | John A. Bartholdson10% owner | Buyindirect · amended | +190,000 | $8.860 | $1.7 M | 3.77 M | Form 4/A |
| filed | Juniper Investment Company, LLC10% owner | Sellindirect | +190,000 | $8.860 | $1.7 M | 3.77 M | Form 4 |
| filed | John A. Bartholdson10% owner | Buyindirect · amended | +120,000 | $8.740 | $1.0 M | 3.58 M | Form 4/A |
| filed | Juniper Investment Company, LLC10% owner | Sellindirect | +120,000 | $8.740 | $1.0 M | 3.58 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Orthofix Medical Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2016 | Q4 2017 | $8.4M |
| Q3 2016 | Q3 2016 | $11.1M |
| Q2 2016 | Q2 2017 | $17.4M |
| Q1 2016 | Q1 2017 | $26.5M |
| Q4 2013 | Q4 2013 | $0M |
| Q3 2013 | Q3 2013 | $12.6M |
Fails to deliver
- : 478 shares at $9.25
- : 485 shares at $9.44
- : 2,508 shares at $9.18
- : 3,942 shares at $8.71
- : 2,861 shares at $8.90
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Orthofix Medical Inc. scorecard#
Passes 8 of the 21 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 15, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.8×Price to book 0.8× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median0.5×Price to sales 0.5× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-0.3%Free cash flow is -0.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year2.9%Revenue up 2.9% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years21.3%21.3% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median21.3%21.3% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-2.33 vs -3.30Diluted EPS -2.33 in fiscal 2025 against -3.30 the year before (report's currency).
- ✗Net income higher than five years earlier-$92 M-$92 M in fiscal 2025 against $3 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$92 MNet income -$92 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-9.9%-9.9% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-19.3%-19.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-9.9%-9.9% in fiscal 2025 against -2.9% in 2022.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.45 at the end of fiscal 2025.
- ✓Debt below equity0.3×Debt to equity 0.35 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone0.96Z-score 0.96 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year3.9%Diluted shares up 3.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Orthofix Medical Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -9.9% | -8.2% | |
| Net margin | -11.2% | -10.4% | |
| Return on equity | -19.3% | -16.8% | |
| Revenue growth, 3 years a year | 21.3% | 10.8% | |
| Revenue growth | 2.9% | 10.4% | |
| Debt to equity | 0.35× | 0.64× |
5of 9on the Piotroski tests of financial strength
- Net loss of $92 million, the 5th loss-making year in a row.
- Free cash flow was negative: -$1 million.
- Revenue has grown 3 years in a row.
Orthofix Medical Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 822+2.9%100% | 799+7.1%100% | 747+62.1%100% | 461−0.8%100% | 464+14.2%100% | 407−11.6%100% | 460+1.5%100% | 453+4.4%100% | 434+5.9%100% | 410—100% | |
| Cost of revenue | 256+1.1%31.2% | 254−2.6%31.7% | 260+111%34.9% | 124+7.5%26.8% | 115+12.8%24.7% | 102+1.3%25.1% | 101+4.1%21.9% | 97+3.9%21.3% | 93+5.9%21.4% | 88—21.4% | |
| Gross profit | 566+3.7%68.8% | 546+12.3%68.3% | 486+44.2%65.1% | 337−3.5%73.2% | 350+14.7%75.3% | 305−15.2%74.9% | 359+0.8%78.1% | 356+4.6%78.7% | 341+5.9%78.6% | 322—78.6% | |
| Research and development | 66−10.6%8.0% | 74−8.2%9.2% | 80+63.5%10.7% | 49−1.1%10.6% | 50+27.1%10.7% | 39+12.8%9.6% | 35+4.3%7.5% | 33+11.8%7.3% | 30+3.1%6.8% | 29—7.0% | |
| Selling, general and administrative | 554+4.1%67.4% | 533+0.4%66.6% | 530+71.8%71.0% | 309—67.0% | — | — | — | — | — | — | |
| Selling and marketing | — | — | 386+68.6%51.7% | 229+3.4%49.7% | 221+8.3%47.6% | 204−8.6%50.3% | 224+8.8%48.6% | 206+3.6%45.4% | 198+9.4%45.7% | 181—44.2% | |
| General and administrative | — | — | 145+80.9%19.4% | 80+15.3%17.4% | 69+2.1%14.9% | 68−20.6%16.7% | 86+2.8%18.6% | 83r85+15.8%18.4% | 72r74−5.9%16.6% | 76r74—18.6% | |
| Operating expenses | — | — | — | — | — | — | 378+15.9%82.2% | 326+8.8%72.0% | 300−0.3%69.1% | 301—73.4% | |
| Operating income | −81—−9.9% | −85—−10.6% | −139—−18.6% | −13—−2.9% | −8.3—−1.8% | −6.3—−1.5% | −19−162%−4.1% | 30−26.3%6.6% | 41+93.7%9.4% | 21—5.1% | |
| Net interest income | −17—−2.1% | −30—−3.7% | −8.6—−1.2% | −1.3—−0.3% | −1.8—−0.4% | −2.5—−0.6% | −0.1—−0.0% | −0.8—−0.2% | −0.4−155%−0.1% | 0.8—0.2% | |
| Provision for credit losses | 2.3+12.8%0.3% | 2.0+144%0.3% | 0.8−60.9%0.1% | 2.1+372%0.5% | 0.4—0.1% | — | — | — | — | — | |
| Other non-operating income (expense) | 8.1—1.0% | −9.6—−1.2% | −0.9—−0.1% | −3.2—−0.7% | −3.3−140%−0.7% | 8.4—2.1% | −8.1—−1.8% | −6.4—−1.4% | −4.0—−0.9% | −2.8—−0.7% | |
| Income before tax | −91—−11.0% | −124—−15.5% | −149—−19.9% | −18—−3.8% | −13—−2.9% | −0.4—−0.1% | −27−218%−5.9% | 23−37.1%5.1% | 36+91.3%8.4% | 19—4.6% | |
| Income tax | 1.4−34.9%0.2% | 2.1−21.9%0.3% | 2.7+32.9%0.4% | 2.0−91.8%0.4% | 25—5.4% | −2.9−304%−0.7% | 1.4−84.4%0.3% | 9.1−68.8%2.0% | 29+87.4%6.7% | 16—3.8% | |
| Income from continuing operations | — | — | — | — | — | — | −28−306%−6.2% | 14+89.4%3.0% | 7.3+108%1.7% | 3.5—0.9% | |
| Net income attributable to shareholders | −92—−11.2% | −126—−15.8% | −151—−20.3% | −20—−4.3% | −38−1625%−8.3% | 2.5—0.6% | −28−306%−6.2% | 14+122%3.0% | 6.2+104%1.4% | 3.1—0.7% | |
| Earnings per share, basic | -2.33—— | -3.30—— | -4.12—— | -0.98—— | -1.95−1600%— | 0.13—— | -1.51−307%— | 0.73+115%— | 0.34+100%— | 0.17—— | |
| Earnings per share, diluted | -2.33—— | -3.30—— | -4.12—— | -0.98—— | -1.95−1600%— | 0.13—— | -1.51−310%— | 0.72+112%— | 0.34+100%— | 0.17—— | |
| Shares, weighted average (basic) | 40+3.9%— | 38+3.8%— | 37+83.2%— | 20+1.8%— | 20+2.2%— | 19+1.9%— | 19+2.2%— | 18+2.1%— | 18−0.1%— | 18—— | |
| Shares, weighted average (diluted) | 40+3.9%— | 38+3.8%— | 37+83.2%— | 20+1.8%— | 20+1.5%— | 19+2.6%— | 19−0.0%— | 19+2.2%— | 18+0.2%— | 18—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 82−1.5%9.6% | 83+151%9.3% | 33−34.7%3.6% | 51−42.3%11.1% | 88−8.8%18.4% | 96+38.1%18.3% | 70+0.1%14.1% | 70−14.2%14.9% | 81+105%20.0% | 40—10.6% | |
| Receivables | 136+0.8%16.0% | 135+5.2%15.1% | 128+54.6%13.8% | 83+5.5%18.1% | 79+8.5%16.5% | 72−16.6%13.8% | 87+11.7%17.5% | 78+22.6%16.7% | 63+9.7%15.6% | 58—15.5% | |
| Inventory | 172−9.0%20.3% | 189−14.7%21.2% | 222+122%24.0% | 100+20.7%21.8% | 83−2.0%17.4% | 85+2.7%16.1% | 82+7.2%16.6% | 77−5.5%16.5% | 81+28.4%20.1% | 63—17.0% | |
| Other current assets | 24+1.2%2.8% | 23−27.9%2.6% | 32+45.5%3.5% | 22+10.6%4.9% | 20+22.1%4.2% | 17−21.2%3.1% | 21+17.3%4.2% | 18−31.0%3.8% | 26+34.5%6.4% | 19—5.2% | |
| Current assets | 417−3.8%49.0% | 433+3.1%48.5% | 420+64.2%45.4% | 256−5.0%55.8% | 270−0.3%56.5% | 270+3.8%51.4% | 261+6.5%52.6% | 245−2.8%52.4% | 252+29.5%62.1% | 194—52.2% | |
| Property, plant and equipment | 129−7.4%15.2% | 140−12.1%15.7% | 159+173%17.2% | 58−1.7%12.7% | 59−6.9%12.4% | 64+1.4%12.1% | 63+46.4%12.7% | 43−5.1%9.2% | 45−7.7%11.1% | 49—13.1% | |
| Right-of-use (leased) assets | 22+29.2%2.6% | 17−13.2%1.9% | 20+193%2.1% | 6.8+115%1.5% | 3.2−34.8%0.7% | 4.8−16.5%0.9% | 5.8—1.2% | — | — | — | |
| Goodwill | 1950.0%22.9% | 1950.0%21.8% | 195+173%21.1% | 710.0%15.6% | 71−15.1%15.0% | 84+18.0%16.0% | 71−1.7%14.4% | 72+35.2%15.5% | 540.0%13.2% | 54—14.4% | |
| Other intangible assets | 73−26.4%8.6% | 99−15.9%11.1% | 117+148%12.7% | 47−10.0%10.3% | 53−13.0%11.0% | 61+11.8%11.5% | 54+4.3%10.9% | 52+396%11.1% | 10+40.2%2.6% | 7.5—2.0% | |
| Total assets | 851−4.8%100% | 893−3.5%100% | 925+102%100% | 459−3.8%100% | 477−9.4%100% | 526+6.1%100% | 496+6.2%100% | 467+15.1%100% | 405+8.9%100% | 372—100% | |
| Accounts payable | 58+19.6%6.9% | 49−16.4%5.5% | 58+111%6.3% | 28+4.3%6.0% | 26+14.5%5.6% | 23+16.3%4.4% | 20+10.5%4.0% | 18−0.7%3.9% | 18+26.2%4.5% | 14—3.9% | |
| Debt due within a year | 0—0.0% | 0−100%0.0% | 1.3—0.1% | — | — | — | — | — | — | — | |
| Current liabilities | 170+1.1%20.0% | 169+2.1%18.9% | 165+97.6%17.9% | 84−21.0%18.2% | 106+1.9%22.2% | 104+22.4%19.8% | 85−1.2%17.1% | 86+8.2%18.4% | 79−4.8%19.6% | 83—22.4% | |
| Long-term debt | 157+0.2%18.5% | 157+68.6%17.6% | 93—10.1% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 25+80.4%3.0% | 14−17.8%1.6% | 17+219%1.9% | 5.4+273%1.2% | 1.4−51.0%0.3% | 2.9−27.9%0.6% | 4.1—0.8% | — | — | — | |
| Total liabilities | 401+2.7%47.1% | 390+19.5%43.7% | 327+168%35.3% | 122−12.8%26.6% | 140−17.3%29.3% | 169+0.6%32.1% | 168+28.0%33.9% | 131+20.7%28.1% | 109+0.1%26.8% | 109—29.2% | |
| Retained earnings | −368—−43.3% | −276—−30.9% | −150−12102%−16.2% | 1.3−94.0%0.3% | 21−64.6%4.4% | 59+2.8%11.3% | 58−33.7%11.7% | 87+23.7%18.7% | 70+9.7%17.4% | 64—17.2% | |
| Shareholders' equity | 450−10.6%52.9% | 503−16.0%56.3% | 599+77.7%64.7% | 337−0.0%73.4% | 337−5.6%70.7% | 357+8.9%67.9% | 328−2.3%66.1% | 335+13.1%71.9% | 297+12.6%73.2% | 263—70.8% | |
| Total liabilities and equity | 851−4.8%100% | 893−3.5%100% | 925+102%100% | 459−3.8%100% | 477−9.4%100% | 526+6.1%100% | 496+6.2%100% | 467+15.1%100% | 405+8.9%100% | 372—100% | |
| Shares outstanding | 40+3.5%— | 38+3.6%— | 37+84.3%— | 20+1.6%— | 20r20+2.1%— | 190.0%— | 19r19+4.5%— | 19+1.6%— | 18+2.5%— | 18—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 77+28.7%9.4% | 60+13.2%7.5% | 53+82.9%7.1% | 29−2.0%6.3% | 30−3.1%6.4% | 31+23.7%7.5% | 25+32.4%5.4% | 19−7.3%4.1% | 20−3.4%4.6% | 21—5.1% | |
| Share-based compensation | 29−11.6%3.5% | 32−9.1%4.1% | 36+93.6%4.8% | 18+19.5%4.0% | 15−4.8%3.3% | 16−24.8%4.0% | 22+13.8%4.7% | 19+50.8%4.2% | 13−21.4%2.9% | 16—3.9% | |
| Cash from operating activities | 33+29.3%4.1% | 26—3.2% | −46—−6.1% | −12−162%−2.5% | 18−75.1%4.0% | 74+132%18.3% | 32−35.8%7.0% | 50+28.1%11.0% | 39r53−34.0%9.0% | 59r45—14.4% | |
| Capital expenditure | −35—−4.2% | −35—−4.4% | −60—−8.1% | −21—−4.6% | −18—−3.8% | −15—−3.8% | −19—−4.1% | −14—−3.0% | −15—−3.4% | −16—−4.0% | |
| Intangible assets bought | — | — | −1.8—−0.2% | −1.8—−0.4% | −1.8—−0.4% | −1.6—−0.4% | −1.5—−0.3% | −1.7—−0.4% | −2.3—−0.5% | −1.9—−0.5% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | −44—−9.8% | — | — | |
| Cash from investing activities | −35—−4.2% | −28—−3.4% | −33—−4.4% | −25—−5.3% | −23—−5.0% | −52—−12.9% | −23—−5.0% | −61—−13.5% | −16—−3.8% | −22—−5.4% | |
| Shares issued | 5.9−5.2%0.7% | 6.3+22.0%0.8% | 5.1+18.2%0.7% | 4.3−50.8%0.9% | 8.8+16.1%1.9% | 7.6−34.2%1.9% | 12+62.7%2.5% | 7.1−8.8%1.6% | 7.8−60.5%1.8% | 20—4.8% | |
| Shares bought back | — | — | — | — | — | — | — | — | — | −63—−15.5% | |
| Cash from financing activities | −0.8−102%−0.1% | 51−22.4%6.3% | 65—8.7% | −0.1—−0.0% | −3.6−212%−0.8% | 3.2—0.8% | −11−457%−2.3% | 3.0−15.4%0.7% | 3.5—0.8% | −46—−11.3% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 1.2—0.3% | −0.7—−0.2% | |
| Change in cash | −0.6−101%−0.1% | 48—6.0% | −13—−1.7% | −37—−8.1% | −9.0−134%−1.9% | 26—6.5% | −1.8—−0.4% | −9.0−133%−2.0% | 27r42—6.3% | −9.7r−24—−2.4% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 835+2.1%100% | 208+1.1%100% | 211+3.8%100% | 197+1.6%100% | 220*+2.0%100% | 206+4.6%100% | 203+2.3%100% | 194+2.7%100% | 216*+7.6%100% | 197—100% | 199—100% | 189—100% | 200*—100% | |
| Cost of revenue | 243−6.3%29.1% | 61+7.4%29.5% | 61−3.7%29.0% | 57−20.6%29.1% | 64*−4.9%28.9% | 57−7.2%27.8% | 64−0.4%31.3% | 72+17.4%37.2% | 67*+4.8%31.0% | 62—31.3% | 64—32.2% | 61—32.5% | 64*—31.8% | |
| Gross profit | 592+6.0%70.9% | 147−1.3%70.5% | 150+7.3%71.0% | 140+14.7%70.9% | 156*+5.0%71.1% | 149+10.0%72.2% | 140+3.6%68.7% | 122−4.4%62.8% | 149*+8.9%69.0% | 135—68.7% | 135—67.8% | 127—67.5% | 137*—68.2% | |
| Research and development | 62−10.6%7.4% | 15+3.4%7.3% | 16+0.1%7.6% | 15−22.5%7.8% | 15*−18.3%7.0% | 15−14.6%7.2% | 16−11.7%7.8% | 20+1.4%10.2% | 19*−0.7%8.7% | 17—8.8% | 18—9.1% | 19—10.3% | 19*—9.5% | |
| Selling, general and administrative | 535−3.4%64.0% | 125−15.4%60.3% | 138+1.1%65.4% | 135+1.5%68.6% | 137*+0.2%62.2% | 148+13.8%72.0% | 136+1.7%67.2% | 133+1.0%68.7% | 136*—63.3% | 130—66.2% | 134—67.6% | 132—69.8% | — | |
| Selling and marketing | — | — | — | — | — | — | — | — | — | 97—49.1% | 100—50.5% | 100—53.0% | 98*—48.8% | |
| General and administrative | — | — | — | — | — | — | — | — | — | 34—17.1% | 34—17.1% | 32—16.8% | 35*—17.2% | |
| Operating expenses | — | — | — | — | — | — | — | — | — | 11—5.5% | 11—5.7% | — | — | |
| Operating income | −21—−2.5% | 1.5—0.7% | −8.1—−3.9% | −14—−7.3% | 0.5*—0.2% | −17—−8.3% | −16—−7.9% | −49—−25.2% | −11*—−5.3% | −19—−9.6% | −25—−12.5% | −29—−15.6% | −18*—−9.1% | |
| Net interest income | −22—−2.6% | −5.9—−2.8% | −6.1—−2.9% | −5.7—−2.9% | −4.4*—−2.0% | −4.7—−2.3% | −4.0—−1.9% | −4.5—−2.3% | −15*—−6.9% | −5.2—−2.6% | −4.9—−2.5% | −4.6—−2.4% | −4.5*—−2.2% | |
| Provision for credit losses | 4.6+92.1%0.6% | 1.2*+97.5%0.6% | 2.9*+269%1.4% | 0.7−32.0%0.4% | −0.2*—−0.1% | 0.6*+29.4%0.3% | 0.8*+295%0.4% | 1.1−23.1%0.5% | −0.1*—−0.0% | 0.5*—0.2% | 0.2*—0.1% | 1.4—0.7% | −0.1*—−0.0% | |
| Other non-operating income (expense) | −0.8−124%−0.1% | −0.9—−0.4% | −0.8−114%−0.4% | −0.7−159%−0.4% | 1.7*—0.8% | −0.5—−0.3% | 5.7—2.8% | 1.2—0.6% | −3.3*−533%−1.5% | −2.5—−1.3% | −2.5—−1.3% | −1.3—−0.7% | 0.8*—0.4% | |
| Income before tax | −43—−5.2% | −5.2—−2.5% | −15—−7.1% | −21—−10.6% | −2.2*—−1.0% | −22—−10.8% | −14—−7.0% | −52—−26.9% | −30*—−13.8% | −27—−13.5% | −32—−16.3% | −35—−18.6% | −22*—−11.0% | |
| Income tax | 1.7+120%0.2% | 0.8+55.0%0.4% | 0.8—0.4% | 0.1−92.3%0.0% | 0.0*—0.0% | 0.5−29.0%0.3% | −0.1−113%−0.1% | 1.0+12.9%0.5% | −0.6*−551%−0.3% | 0.8—0.4% | 1.1—0.5% | 0.9—0.5% | 0.1*—0.1% | |
| Net income attributable to shareholders | −45—−5.4% | −6.1—−2.9% | −16—−7.5% | −21—−10.6% | −2.2*—−1.0% | −23—−11.1% | −14—−6.9% | −53—−27.4% | −29*—−13.5% | −27—−13.9% | −33—−16.8% | −36—−19.1% | −22*—−11.1% | |
| Earnings per share, basic | — | -0.15—— | -0.39—— | -0.52—— | — | -0.57—— | -0.36—— | -1.35—— | — | -0.71—— | -0.88—— | -0.95—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.39—— | -0.52—— | — | -0.57—— | -0.36—— | -1.35—— | — | -0.71—— | -0.88—— | -0.95—— | — | |
| Shares, weighted average (basic) | 41+3.6%— | 41+3.6%— | 41+3.6%— | 40+3.2%— | — | 40+3.3%— | 40+3.9%— | 39+3.8%— | — | 38—— | 38r0.0—— | 38r0.0—— | — | |
| Shares, weighted average (diluted) | 41+3.6%— | 41+3.6%— | 41+3.6%— | 40+3.2%— | — | 40+3.3%— | 40+3.9%— | 39+3.8%— | — | 38—— | 38r0.0—— | 38r0.0—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 86—10.1% | 86+37.3%10.1% | 104+58.2%11.9% | 120+108%13.6% | 82−1.5%9.6% | 63+109%7.5% | 66+149%7.8% | 58+115%7.0% | 83+151%9.3% | 30—3.5% | 26—3.0% | 27—3.0% | 33—3.6% | |
| Receivables | 132—15.4% | 132+0.7%15.4% | 136+4.8%15.6% | 138+4.5%15.5% | 136+0.8%16.0% | 131+4.8%15.7% | 130+3.3%15.5% | 132+5.0%16.0% | 135+5.2%15.1% | 125—14.4% | 125—14.2% | 126—13.9% | 128—13.8% | |
| Inventory | 190—22.2% | 190+9.4%22.2% | 184+6.6%21.1% | 178+1.9%20.1% | 172−9.0%20.3% | 174−15.4%20.9% | 173−17.6%20.7% | 174−20.4%21.2% | 189−14.7%21.2% | 206—23.7% | 210—23.8% | 219—24.2% | 222—24.0% | |
| Other current assets | 22—2.5% | 22−6.8%2.5% | 21−12.8%2.5% | 25+6.6%2.8% | 24+1.2%2.8% | 23+1.6%2.8% | 25+12.8%2.9% | 24−5.3%2.9% | 23−27.9%2.6% | 23—2.7% | 22—2.5% | 25—2.7% | 32—3.5% | |
| Current assets | 431—50.3% | 431+9.3%50.3% | 446+12.7%51.1% | 462+18.2%52.1% | 417−3.8%49.0% | 394+2.1%47.3% | 396+2.5%47.3% | 390−2.2%47.4% | 433+3.1%48.5% | 386—44.5% | 386—43.8% | 399—44.0% | 420—45.4% | |
| Property, plant and equipment | 133—15.6% | 133+2.6%15.6% | 131+1.2%15.0% | 125−4.1%14.1% | 129−7.4%15.2% | 130−11.4%15.6% | 129−16.2%15.4% | 131−17.4%15.9% | 140−12.1%15.7% | 147—16.9% | 154—17.5% | 158—17.5% | 159—17.2% | |
| Right-of-use (leased) assets | 21—2.4% | 21−12.7%2.4% | 21−15.9%2.4% | 22+30.0%2.4% | 22+29.2%2.6% | 24+32.7%2.9% | 25+33.8%3.0% | 17−13.2%2.0% | 17−13.2%1.9% | 18—2.1% | 19—2.1% | 19—2.1% | 20—2.1% | |
| Goodwill | 195—22.8% | 1950.0%22.8% | 1950.0%22.3% | 1950.0%22.0% | 1950.0%22.9% | 1950.0%23.4% | 1950.0%23.3% | 1950.0%23.7% | 1950.0%21.8% | 195—22.5% | 195—22.1% | 195—21.5% | 195—21.1% | |
| Other intangible assets | 63—7.4% | 63−16.8%7.4% | 66−16.4%7.6% | 69−14.6%7.8% | 73−26.4%8.6% | 76−27.6%9.1% | 79−27.2%9.4% | 81−28.0%9.9% | 99−15.9%11.1% | 105—12.0% | 108—12.3% | 113—12.4% | 117—12.7% | |
| Total assets | 856—100% | 856+2.8%100% | 873+4.3%100% | 887+7.7%100% | 851−4.8%100% | 833−4.1%100% | 837−5.1%100% | 823−9.2%100% | 893−3.5%100% | 868—100% | 882—100% | 906—100% | 925—100% | |
| Accounts payable | 58—6.8% | 58+15.0%6.8% | 64+40.9%7.3% | 55+21.1%6.2% | 58+19.6%6.9% | 50+7.2%6.1% | 45−10.5%5.4% | 45−20.9%5.5% | 49−16.4%5.5% | 47—5.4% | 50—5.7% | 57—6.3% | 58—6.3% | |
| Debt due within a year | — | — | — | — | 0—0.0% | — | — | — | 0−100%0.0% | 6.3—0.7% | 4.7—0.5% | 3.1—0.3% | 1.3—0.1% | |
| Current liabilities | 138—16.2% | 138−13.4%16.2% | 157+5.8%18.0% | 161+11.7%18.2% | 170+1.1%20.0% | 160−1.3%19.2% | 148−4.9%17.7% | 144−4.3%17.5% | 169+2.1%18.9% | 162—18.7% | 156—17.7% | 151—16.6% | 165—17.9% | |
| Long-term debt | 222—25.9% | 222+41.1%25.9% | 222+41.1%25.4% | 221+41.1%25.0% | 157+0.2%18.5% | 157+40.1%18.9% | 157+38.6%18.8% | 157+36.3%19.1% | 157+68.6%17.6% | 112—12.9% | 113—12.8% | 115—12.7% | 93—10.1% | |
| Lease liabilities (non-current) | 24—2.8% | 24−8.1%2.8% | 24−8.3%2.8% | 25+86.6%2.8% | 25+80.4%3.0% | 26+73.6%3.1% | 26+68.0%3.2% | 13−19.0%1.6% | 14−17.8%1.6% | 15—1.7% | 16—1.8% | 16—1.8% | 17—1.9% | |
| Total liabilities | 426—49.8% | 426+9.2%49.8% | 444+17.2%50.8% | 451+23.7%50.9% | 401+2.7%47.1% | 390+14.1%46.9% | 379+12.7%45.2% | 365+8.7%44.3% | 390+19.5%43.7% | 342—39.4% | 336—38.1% | 336—37.1% | 327—35.3% | |
| Retained earnings | −411—−48.0% | −411—−48.0% | −405—−46.4% | −389—−43.9% | −368—−43.3% | −366—−44.0% | −343—−41.0% | −329—−40.0% | −276—−30.9% | −247—−28.5% | −220—−24.9% | −186—−20.5% | −150—−16.2% | |
| Shareholders' equity | 430—50.2% | 430−2.9%50.2% | 429−6.4%49.2% | 435−5.0%49.1% | 450−10.6%52.9% | 442−15.9%53.1% | 458−16.1%54.8% | 458−19.6%55.7% | 503−16.0%56.3% | 526—60.6% | 546—61.9% | 570—62.9% | 599—64.7% | |
| Total liabilities and equity | 856—100% | 856+2.8%100% | 873+4.3%100% | 887+7.7%100% | 851−4.8%100% | 833−4.1%100% | 837−5.1%100% | 823−9.2%100% | 893−3.5%100% | 868—100% | 882—100% | 906—100% | 925—100% | |
| Shares outstanding | 41—— | 41+3.1%— | 41+3.2%— | 40+3.3%— | 40+3.5%— | 40+3.4%— | 39+3.8%— | 39+4.5%— | 38+3.6%— | 38—— | 38—— | 37—— | 37—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 53−33.9%6.3% | 13+1.8%6.3% | 13−21.3%6.3% | 13−60.8%6.9% | 13*−18.2%5.9% | 13−14.7%6.3% | 17+20.2%8.3% | 34+132%17.8% | 16*+14.5%7.4% | 15—7.7% | 14—7.1% | 15—7.9% | 14*—7.0% | |
| Share-based compensation | 28−1.4%3.4% | 6.7−6.1%3.2% | 7.7−1.1%3.7% | 6.5+1.0%3.3% | 7.2*+0.7%3.3% | 7.2+10.0%3.5% | 7.8−21.4%3.9% | 6.5−26.5%3.3% | 7.2*+126%3.3% | 6.5—3.3% | 10.0—5.0% | 8.8—4.7% | 3.2*—1.6% | |
| Cash from operating activities | 4.2−85.6%0.5% | 0.4*−97.1%0.2% | −6.2*−153%−3.0% | −18—−9.0% | 28*+16.7%12.6% | 12*+6.3%6.0% | 12*+29.6%5.7% | −18—−9.5% | 24*—11.0% | 12*—5.9% | 9.0*—4.5% | −19—−9.9% | −6.7*—−3.3% | |
| Capital expenditure | −49—−5.8% | −15*—−7.0% | −13*—−6.0% | −11—−5.4% | −11*—−4.9% | −9.9*—−4.8% | −7.1*—−3.5% | −6.7—−3.5% | −8.5*—−4.0% | −5.3*—−2.7% | −9.3*—−4.7% | −11—−5.6% | −15*—−7.3% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | — | −0.5*—−0.2% | −0.4*—−0.2% | −0.3—−0.1% | −0.5*—−0.2% | |
| Cash from investing activities | −49—−5.8% | −15*—−7.0% | −13*—−6.0% | −11—−5.3% | −11*—−4.9% | −9.9*—−4.8% | −7.1*—−3.5% | −6.7—−3.5% | −1.1*—−0.5% | −5.9*—−3.0% | −9.7*—−4.9% | −11—−5.8% | −15*—−7.5% | |
| Shares issued | — | 0*−100%0.0% | — | — | 2.8*−3.6%1.3% | 0.0*−70.0%0.0% | 3.0*—1.5% | 0.0—0.0% | 2.9*+7.1%1.4% | 0.1*—0.1% | — | — | 2.8*—1.4% | |
| Cash from financing activities | 66+132%7.9% | −3.2*—−1.5% | 2.5*−7.2%1.2% | 64—32.5% | 2.4*−92.5%1.1% | −5.2*—−2.5% | 2.6*+1073%1.3% | −0.7−103%−0.3% | 31*+24.6%14.6% | −2.5*—−1.2% | 0.2*—0.1% | 21—11.4% | 25*—12.6% | |
| Change in cash | 21−37.2%2.5% | −17*—−8.4% | −16*−300%−7.8% | 36—18.2% | 19*−64.0%8.7% | −2.7*−174%−1.3% | 8.2*—4.1% | −25—−13.1% | 53*+1199%24.7% | 3.7*—1.9% | −0.6*—−0.3% | −8.3—−4.4% | 4.1*—2.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Orthofix Medical Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Global Spine$688 M84%+1.8%
- Global Limb Reconstruction$135 M16%+8.4%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Orthofix Medical Inc. operates: 10 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 11 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | $684 M83% |
| 🇨🇭 Switzerland | 2 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
| 🇨🇦 Canada | 1 subsidiary | — |
| 🇳🇱 Netherlands | 1 subsidiary | — |
| 🇮🇹 Italy | 1 subsidiary | $22 M2.7% |
| 🇬🇧 UK | $13 M1.6% | |
| 🇫🇷 France | 1 subsidiary | $12 M1.4% |
| 🇩🇪 Germany | 2 subsidiaries | $9 M1.1% |
| 🇧🇷 Brazil | 1 subsidiary | $5 M0.6% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Orthofix Medical Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Massimo Calafiore | $7.3 M | $3.3 M | $2.2 M | $35 (peers $104) |
| 2024Massimo Calafiore | $10.6 M | $14.6 M | $2.7 M | $38 (peers $150) |
| 2023Massimo Calafiore | $15.6 M | $2.3 M | $2.3 M | $29 (peers $130) |
| 2022Massimo Calafiore | $6.3 M | $5.0 M | $2.1 M | $44 (peers $121) |
| 2021Massimo Calafiore | $5.3 M | $723 K | $1.8 M | $67 (peers $170) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Orthofix Medical Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 3 · Agreement ended 2 · New debt 1 · Shareholder vote 3 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
1 acquisitions, $377 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| SeaSpine Holdings Corporation | 2025 | — | $377 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Orthofix Medical Inc. compares in Medical Devices
- Market cap$377 M · higher than 46% of 142
- Revenue$822 M · higher than 79% of 155
- Net margin-5.4% · higher than 50% of 144
- Revenue growth2.9% · higher than 27% of 104
- Price / sales0.5× · lower than 96% of 96
- Price / book0.8× · lower than 89% of 99
- FCF yield-0.3% · higher than 55% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Orthofix Medical Inc.🇺🇸 | $377 M | — | -5.4% | +2.9% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 15, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Orthofix Medical Inc.? Verify and update this profile — free
Show Orthofix Medical Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.